Quotient Sciences advances AI-designed drug product into Phase I clinical study
Company launches clinical study of AI-designed oral formulation following MHRA approval, marking a major milestone in AI-driven drug development.
Company launches clinical study of AI-designed oral formulation following MHRA approval, marking a major milestone in AI-driven drug development.
The device screens for conditions like diabetic retinopathy, glaucoma, age-related macular degeneration, cataract and refractive error, in under ten minutes per patient
A one-shot gene-editing cholesterol therapy could soon be a reality
The findings support the continued advancement of EB-003, a first-in-class neuroplastogen designed to selectively target both 5-HT2A and 5-HT1B receptors
Solutions designed to help clinicians reduce administrative burden, improve diagnostic accuracy, and spend more time with patients
The platform combines internally developed technologies, strategic partnerships, and external AI capabilities
Access to genomic testing, not therapy cost, is the biggest challenge
Precision medicine company advances Raman spectroscopy-based therapeutic drug monitoring platform for rapid, patient-specific dosing solutions
Study introduces structured, condition-specific emergency coding system to improve coordination, response time, and patient safety in tertiary care hospitals
With the convergence of AI, robotics, and neuroscience, Motorica is advancing toward more intuitive, intent-driven prosthetic systems
Subscribe To Our Newsletter & Stay Updated